Loading...
Loading...
Available on 2 platforms
Sign in to view source links and access this dataset
11,276 patients diagnosed with advanced gastric cancer in Japan between September 2021 and September 2024 were analyzed for treatment patterns and time-to-treatment discontinuation. The dataset captures real-world clinical practice following the 2021 approval of first-line nivolumab, detailing the most common regimens across first, second, and third lines of therapy. It enables analysis of outcomes for different patient groups, including HER2-positive and HER2-negative cohorts treated with various chemotherapy and immunotherapy combinations.
License is CC-BY-4.0, requiring attribution. Primary file formats listed are JPG and DOCX, which suggests the dataset may include document and image files (e.g., study figures, manuscript) rather than or in addition to raw analytical data.